Recent Advances in Research on the Relationship between Gut Microbiota, Its Metabolites, and Acute Myeloid Leukemia--Review.
10.19746/j.cnki.issn.1009-2137.2025.03.044
- Author:
Lei-Lei KONG
1
;
Jian LI
1
Author Information
1. Key Laboratory of Hematology, The Second Affiliated Hospital of Nanchang University,Nanchang 330006, Jiangxi Province, China.
- Publication Type:English Abstract
- Keywords:
acute myeloid leukemia;
gut microbiota;
metabolites;
treatment;
prognosis
- MeSH:
Humans;
Leukemia, Myeloid, Acute/metabolism*;
Gastrointestinal Microbiome;
Hematopoietic Stem Cell Transplantation;
Graft vs Host Disease
- From:
Journal of Experimental Hematology
2025;33(3):913-917
- CountryChina
- Language:Chinese
-
Abstract:
Gut microbiota and its metabolites are associated with a variety of hematological malignancies, including acute myeloid leukemia (AML). AML patients commonly suffer from imbalances in intestinal homeostasis before and after chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT). The diversity and abundance of gut microbiota, as well as the levels of metabolites, may be biomarkers for predicting the occurrence of infection and graft-versus-host disease (GVHD) in AML patients. In order to offer a theoretical foundation for optimizing treatment strategies for AML patients, this review summarized the latest research progress on gut microbiota and its metabolites in relation to the occurrence, development, treatment and prognosis of AML.
